C3N-01414
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 58.13004791
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.460
- OXIDATIVE_PHOSPHORYLATION+0.360
- ESTROGEN_RESPONSE_EARLY+0.320
- TNFA_SIGNALING_VIA_NFKB+0.290
- ANGIOGENESIS+0.250
- ADIPOGENESIS+0.230
- UV_RESPONSE_DN+0.230
- MYC_TARGETS_V2+0.210
- PANCREAS_BETA_CELLS+0.200
- ANDROGEN_RESPONSE+0.180
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.380
- E2F_TARGETS-0.280
- INTERFERON_GAMMA_RESPONSE-0.270
- GLYCOLYSIS-0.240
- INTERFERON_ALPHA_RESPONSE-0.220
- COMPLEMENT-0.200
- APICAL_JUNCTION-0.180
- G2M_CHECKPOINT-0.180
- IL6_JAK_STAT3_SIGNALING-0.170
- APICAL_SURFACE-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4ea93d27-97e3-40bd-8734-d026e48fbbe4 | — | — | 0.657 |
| 2 | TCGA-BH-A0H6-01A-21R-A056-07 | — | A | 0.651 |
| 3 | MNG999 | — | — | 0.650 |
| 4 | da1c4d8d-b07a-4aa1-8360-1c140ca16327 | — | — | 0.642 |
| 5 | R148 | — | — | 0.637 |
| 6 | TCGA-J2-8194-01A-11R-2241-07 | — | cohortA2 | 0.634 |
| 7 | SRR10899980 | — | — | 0.632 |
| 8 | TCGA-IQ-7632-01A-11R-2081-07 | — | — | 0.631 |
| 9 | TCGA-44-7671-01A-11R-2066-07 | — | cohortA2 | 0.630 |
| 10 | SRR10842375 | — | — | 0.628 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.460 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.320 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.210 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.140 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.130 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |